Loading clinical trials...
Loading clinical trials...
A Phase 2, Double Blind, Placebo-Controlled Study to Explore the Safety, Tolerability, and Activity of SXC-2023 in Adults With Moderate to Severe Trichotillomania (TTM) When Dosed for 6 Weeks
Conditions
Interventions
SXC-2023
Placebo
Locations
13
United States
CNRI- Los Angeles
Pico Rivera, California, United States
Artemis Institute for Clinical Research
Riverside, California, United States
Behavioral Clinical Research
North Miami, Florida, United States
iResearch Atlanta
Decatur, Georgia, United States
Univ of Chicago
Chicago, Illinois, United States
Lake Charles Clinical Trials
Lake Charles, Louisiana, United States
Start Date
December 19, 2018
Primary Completion Date
December 2, 2019
Completion Date
December 16, 2019
Last Updated
October 28, 2021
NCT07224126
NCT05003401
NCT04241120
NCT01875445
NCT00354770
NCT03530800
Lead Sponsor
Promentis Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions